Cas:31694-94-7 1-[(4-chlorophenyl)methyl]tetrazol-5-amine manufacturer & supplier

We serve Chemical Name:1-[(4-chlorophenyl)methyl]tetrazol-5-amine CAS:31694-94-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-[(4-chlorophenyl)methyl]tetrazol-5-amine

Chemical Name:1-[(4-chlorophenyl)methyl]tetrazol-5-amine
CAS.NO:31694-94-7
Synonyms:chlorobenzyltetraazolylamine;1-(4-chlorobenzyl)-1H-1,2,3,4-tetraazol-5-ylamine;1-(4-chlorobenzyl)-1h-tetrazol-5-amine;1-(4-chloro-benzyl)-1H-tetrazol-5-ylamine
Molecular Formula:C8H8ClN5
Molecular Weight:209.63600
HS Code:2933990090

Physical and Chemical Properties:
Melting point:201-203ºC
Boiling point:422.3ºC at 760mmHg
Density:1.54g/cm3
Index of Refraction:1.728
PSA:69.62000
Exact Mass:209.04700
LogP:1.53820

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like chlorobenzyltetraazolylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(4-chloro-benzyl)-1H-tetrazol-5-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,chlorobenzyltetraazolylamine Use and application,1-(4-chlorobenzyl)-1H-1,2,3,4-tetraazol-5-ylamine technical grade,usp/ep/jp grade.


Related News: Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday. (4-amino-2-methylpyrimidin-5-yl)methanethiol manufacturers The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. (Z)-2-methyl-1-phenylbut-2-en-1-one suppliers Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments. N’,2-bis((5-methylfuran-2-yl)methylene)hydrazine-1-carbohydrazide vendor & factory In response, the strategy sets out how government will work with institutions, businesses, funders and charities to drive change in the sector, with new initiatives to encourage more young people into research, broaden career pathways in the sector and look further into the impacts of bureaucracy on researchers.,The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus.